
Suzuken Co Ltd (9987) - Financial and Strategic SWOT Analysis Review
Description
Suzuken Co Ltd (9987) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Suzuken Co Ltd (Suzuken) is a distributor of pharmaceuticals, medical equipment and supplies, diagnostic reagents, and medical foods. The company's activities extend to the comprehensive development of medical and health-related businesses, including the research, development, and manufacturing of new drugs. The company has pipeline products that are useful for the treatment of type II diabetes, chronic kidney diseases and other dialysis-related areas with substantial unmet medical needs. It also provides support services for pharmaceutical manufacturers and operates pharmacy and nursing care businesses. Suzuken boasts a comprehensive distribution function, referred to as the healthcare distribution platform, which extends from pharmaceutical manufacturers to wholesalers, medical institutions, and pharmacies. Suzuken is headquartered in Nagoya, Aichi, Japan.
Suzuken Co Ltd Key Recent Developments
Aug 13,2025: Suzuken Consolidated Financial Results for the Three Months Ended June 30, 2025
May 13,2025: Notice of Relocation of Fukuoka Sales Department Higashi Fukuoka Branch
May 13,2025: Business alliance with Dongwon Pharmaceutical Group and Notice of Group's Investment in Gyeongnam Dongwon Pharmaceutical
May 13,2025: Suzuken Announces Consolidated Financial Results for the Year Ended March 31, 2025
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Suzuken Co Ltd (Suzuken) is a distributor of pharmaceuticals, medical equipment and supplies, diagnostic reagents, and medical foods. The company's activities extend to the comprehensive development of medical and health-related businesses, including the research, development, and manufacturing of new drugs. The company has pipeline products that are useful for the treatment of type II diabetes, chronic kidney diseases and other dialysis-related areas with substantial unmet medical needs. It also provides support services for pharmaceutical manufacturers and operates pharmacy and nursing care businesses. Suzuken boasts a comprehensive distribution function, referred to as the healthcare distribution platform, which extends from pharmaceutical manufacturers to wholesalers, medical institutions, and pharmacies. Suzuken is headquartered in Nagoya, Aichi, Japan.
Suzuken Co Ltd Key Recent Developments
Aug 13,2025: Suzuken Consolidated Financial Results for the Three Months Ended June 30, 2025
May 13,2025: Notice of Relocation of Fukuoka Sales Department Higashi Fukuoka Branch
May 13,2025: Business alliance with Dongwon Pharmaceutical Group and Notice of Group's Investment in Gyeongnam Dongwon Pharmaceutical
May 13,2025: Suzuken Announces Consolidated Financial Results for the Year Ended March 31, 2025
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
54 Pages
- Section 1 - About the Company
- Suzuken Co Ltd - Key Facts
- Suzuken Co Ltd - Key Employees
- Suzuken Co Ltd - Key Employee Biographies
- Suzuken Co Ltd - Key Operational Employees
- Suzuken Co Ltd - Major Products and Services
- Suzuken Co Ltd - History
- Suzuken Co Ltd - Company Statement
- Suzuken Co Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Suzuken Co Ltd - Business Description
- Business Segment: Community Healthcare and Nursing Care Support
- Overview
- Performance
- Business Segment: Healthcare Product Development
- Overview
- Performance
- Business Segment: Healthcare-Related Services
- Overview
- Performance
- Business Segment: Pharmaceutical Distribution
- Overview
- Performance
- R&D Overview
- Suzuken Co Ltd - Corporate Strategy
- Suzuken Co Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Suzuken Co Ltd - Strengths
- Suzuken Co Ltd - Weaknesses
- Suzuken Co Ltd - Opportunities
- Suzuken Co Ltd - Threats
- Suzuken Co Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
- Suzuken Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Suzuken Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Suzuken Co Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Aug 13, 2025: Suzuken Consolidated Financial Results for the Three Months Ended June 30, 2025
- May 13, 2025: Notice of Relocation of Fukuoka Sales Department Higashi Fukuoka Branch
- May 13, 2025: Business alliance with Dongwon Pharmaceutical Group and Notice of Group's Investment in Gyeongnam Dongwon Pharmaceutical
- May 13, 2025: Suzuken Announces Consolidated Financial Results for the Year Ended March 31, 2025
- Apr 24, 2025: Notice of Integration of Saitama Sales Department Urawa Branch
- Mar 10, 2025: Nine Suzuken Group Selected as 2025 Certified Health & Productivity Management Organizations
- Feb 12, 2025: Suzuken Announces Consolidated Financial Statements for the Third Quarter of the Fiscal Year Ending March 31, 2025
- Nov 12, 2024: Suzuken : Consolidated Financial Statements for the Second Quarter (Interim Period) of the Fiscal Year Ending March 31, 2025 (Japanese Standard)
- Nov 12, 2024: Suzuken Announces 2Q Consolidated Cumulative Period Ended September 30, 2024 (Interim Period), and Revision to Consolidated Financial Forecast for the Year Ending March 31, 2025
- Nov 11, 2024: Notice Regarding the Relocation of the Karatsu Branch of the Saga Sales Department
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Suzuken Co Ltd, Key Facts
- Suzuken Co Ltd, Key Employees
- Suzuken Co Ltd, Key Employee Biographies
- Suzuken Co Ltd, Key Operational Employees
- Suzuken Co Ltd, Major Products and Services
- Suzuken Co Ltd, History
- Suzuken Co Ltd, Subsidiaries
- Suzuken Co Ltd, Key Competitors
- Suzuken Co Ltd, Ratios based on current share price
- Suzuken Co Ltd, Annual Ratios
- Suzuken Co Ltd, Annual Ratios (Cont...1)
- Suzuken Co Ltd, Annual Ratios (Cont...2)
- Suzuken Co Ltd, Interim Ratios
- Suzuken Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Suzuken Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Suzuken Co Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Suzuken Co Ltd, Performance Chart (2021 - 2025)
- Suzuken Co Ltd, Ratio Charts
- Suzuken Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Suzuken Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.